Real-World Outcome Research Study on Quality of Life, Work Productivity and Health Care Resource Utilization in Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Registration Number
- NCT02315365
- Lead Sponsor
- PeriPharm
- Brief Summary
This real-life Health Economics and Outcome Research (HEOR) study will enable to assess the impact of current therapies on quality of life (QoL), productivity loss and health care resource utilization in metastatic breast cancer (mBC). This prospective study will estimate patient-reported outcomes (PROs) and resource utilization data for mBC patients stratified according to treatment type, treatment line and disease status (progression vs. progression free) in a real-life setting.
To estimate QoL, work productivity and health care resource utilization of post-menopausal patients with ER+/HER2- locally advanced or metastatic breast cancer in a real-life setting. The secondary objective is to estimate QoL and work productivity of mBC patients' caregivers.
During the course of the study, data will be collected on quality of life and work productivity. Patients and caregivers will be asked to fill a set of questionnaires at their recruitment in the study, at 3 months and at 6 months after recruitment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 202
- Diagnosis of locally advanced or metastatic breast cancer
- Post-menopausal women
- ER+/HER2- mBC
- Signature of informed consent form
- Ability to read and understand English or French
- Participation to a clinical trial
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pharmacoeconomic impact of current therapies for the treatment of mBC in a real-life setting. 6-month follow-up after recruitment Pharmacoeconomic impact will be evaluated by questionnaires completed by the patient and the caregiver. These include quality of life, health care resource utilization, work productivity and activity impairment, and health questionnaires. Data will be summarized by time points (recruitment, 3 months and 6 months) and categorized by the line of treatment (first line, second and subsequent line), by disease status (progression and progression free), by treatment type (chemotherapy and endocrine therapy, and if sample size permits by type of endocrine therapy such as anti-estrogen and aromatase inhibitors), and by specific treatment (such as letrozole and anastrozole), if sample size permits.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (5)
Kingston General Hospital
🇨🇦Kingston, Ontario, Canada
CISSS de la Montérégie-Centre (Hôpital Charles Lemoyne)
🇨🇦Greenfield Park, Quebec, Canada
CIUSSS de l'Est-de-l'Île-de-Montréal (Hôpital Maisonneuve-Rosemont)
🇨🇦Montreal, Quebec, Canada
CSSS Alphonse-Desjardins
🇨🇦Lévis, Quebec, Canada
CHU de Québec (Hôpital du Saint-Sacrement)
🇨🇦Québec, Quebec, Canada